Src Kinase Inhibitor Peptide Binding Site Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer and cell proliferation disorders often face challenges such as resistance to existing kinase inhibitors, cardiotoxicity, and limited efficacy across various cancer types, highlighting the need for a more potent and selective Src tyrosine kinase inhibitor.
Innovation Solution
The development of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (compound (I)) and its pharmaceutically acceptable salts, which act as a highly selective Src tyrosine kinase inhibitor targeting the peptide substrate-binding site, rather than the ATP-binding site, thereby offering enhanced potency and reduced cardiotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ATP-binding site kinase inhibitors are used, then kinase activity is inhibited, but cardiotoxicity occurs and resistance develops
Solution Approach 1:
The patent extracts the inhibitory function from the ATP-binding site and relocates it to the peptide substrate-binding site. Compound (I) specifically targets the peptide substrate-binding site of Src kinase, separating the therapeutic effect (kinase inhibition) from the harmful effects (cardiotoxicity and resistance) associated with ATP-competitive inhibitors
Solution Approach 2:
The invention applies local quality by making the inhibition highly specific to the peptide substrate-binding site rather than the general ATP-binding site. This localized targeting approach allows selective inhibition of Src kinase while sparing other kinases, thereby reducing cardiotoxicity and overcoming resistance to broad-spectrum ATP-competitive inhibitors
2Adaptability or versatility
If broad-spectrum kinase inhibitors are used, then multiple cancer types are targeted, but selectivity is reduced leading to off-target effects
Solution Approach 1:
The patent employs local quality by designing compound (I) to act specifically at the peptide substrate-binding site of Src kinase. This localized mechanism provides high selectivity for Src while maintaining versatility in treating multiple cancer types that rely on Src signaling, without the off-target effects of broad-spectrum ATP-competitive inhibitors
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
The invention relates to a pharmaceutical composition comprising 2-(5-(4-(2- mopholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.